Vijaya L. Damaraju - Concepedia

Author

Vijaya L. Damaraju

Also Known As

V. Damaraju, V. L. Damaraju, V.L. Damaraju, VIJAYA L. DAMARAJU, Vijaya Damaraju, Vijaya L Damaraju, Vijaya L. Damaraju, Vijaya L Damaraju

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

University of Alberta Brigham Young University Alberta Cancer Foundation University of Leeds Indiana University School of Medicine

About

Vijaya L. Damaraju is an author at University of Alberta specializing in medicine, pharmacology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	488
2	Biochemistry	4	4	117
3	Natural Sciences	2	2	85
4	Engineering	1	1	12
5	Health Sciences	1	1	158

Vijaya L. Damaraju

Publications

Citations

H-Index

Page 1

	Year	Citations
An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity Carla M. Prado, Isac Lima, Vickie E. Baracos, Cancer Chemotherapy and Pharmacology Exploratory StudyBody CompositionHealth SciencesPharmacological StudyMedicine	2010	158
A Comparison of the Transportability, and Its Role in Cytotoxicity, of Clofarabine, Cladribine, and Fludarabine by Recombinant Human Nucleoside Transporters Produced in Three Model Expression Systems Karen King, Vijaya L. Damaraju, Mark F. Vickers, Molecular Pharmacology	2005	99
Two Distinct Molecular Mechanisms Underlying Cytarabine Resistance in Human Leukemic Cells Jie Cai, Vijaya L. Damaraju, Normand Groulx, Cancer Research	2008	89
Role of Human Nucleoside Transporters in the Uptake and Cytotoxicity of Azacitidine and Decitabine Vijaya L. Damaraju, Delores Mowles, Sylvia Y.M. Yao, Nucleosides Nucleotides & Nucleic Acids Pharmaceutical ScienceCellular PharmacologyPharmacotherapyTranslational PharmacologyDrug Resistance	2012	62
Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine Xing-Xiang Peng, Zhi Shi, Vijaya L. Damaraju, Leukemia Research Signal TransductionCell SignalingMedicineCell TraffickingAutophagy	2007	60
Localization of broadly selective equilibrative and concentrative nucleoside transporters, hENT1 and hCNT3, in human kidney Vijaya L. Damaraju, Adam Elwi, Charlene Hunter, American Journal of Physiology-Renal Physiology	2007	56
Residues 334 and 338 in Transmembrane Segment 8 of Human Equilibrative Nucleoside Transporter 1 Are Important Determinants of Inhibitor Sensitivity, Protein Folding, and Catalytic Turnover Frank Visser, Lijie Sun, Vijaya L. Damaraju, Journal of Biological Chemistry	2007	46
Erlotinib, Gefitinib, and Vandetanib Inhibit Human Nucleoside Transporters and Protect Cancer Cells from Gemcitabine Cytotoxicity Vijaya L. Damaraju, Tara Scriver, Delores Mowles, Clinical Cancer Research	2013	40
Improved Syntheses of 5′-<i>S</i>-(2-Aminoethyl)-6-<i>N</i>-(4-nitrobenzyl)-5′-thioadenosine (SAENTA), Analogues, and Fluorescent Probe Conjugates: Analysis of Cell-Surface Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels for Prediction of the Antitumor Efficacy of Gemcitabine Morris J. Robins, Yunshan Peng, Vijaya L. Damaraju, Journal of Medicinal Chemistry	2010	34
The Role of Human Nucleoside Transporters in Cellular Uptake of 4′-Thio-β-d-arabinofuranosylcytosine and β-d-Arabinosylcytosine Marilyn L. Clarke, Vijaya L. Damaraju, Jing Zhang, Molecular Pharmacology	2006	32

Page 1